In this episode of the CFI bio Journal Club, we cover one of the key clinical trials that supported the recent FDA approval of the first prescription video game. The game was developed by Akili Interactive, is called EndeavorRx, and is now a clinically-validated therapy for improving attention in children with Attention Deficit Hyperactivity Disorder (ADHD).
But how does a game improve attention? How does a clinical trial evaluate the efficacy of a game? And what are the pros and cons of a video game as compared to traditional pharmacological therapies for ADHD? Bio deal team partner Justin Larkin and Lauren Richardson delve into these questions and more in their discussion of this clinical trial:
“A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial” in Lancet Digital Health (April 2020) by Scott H Kollins, Denton J DeLoss, Elena Cañadas, Jacqueline Lutz, Robert L Findling, Richard S E Keefe, Jeffery N Epstein, Andrew J Cutler, and Stephen V Faraone.
CFI bio Journal Club (part of the CFI Podcast), curates and covers recent advances from the scientific literature — what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at CFI .com/journalclub.
The CFI Podcast discusses the most important ideas within technology with the people building it. Each episode aims to put listeners ahead of the curve, covering topics like AI, energy, genomics, space, and more.